Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study

Table 1 Baseline data of patients and pre-treatment liver function levels (n = 165)

Clinical data	Number of cases (%)
Age
< 60 years old	92 (55.8)
≥ 60 years old	73 (44.2)
Gender
Male	126 (76.4)
Female	39 (23.6)
Viral hepatitis
Hepatitis B	119 (72.2)
Hepatitis C	37 (22.4)
Hepatitis B comorbidities	3 (1.8)
Hepatitis C
None	6 (3.6)
Child-Pugh
A-level	136 (82.4)
B/C level	27/2 (16.4/1.2)
Tumor staging
0/A/B	5/62/65 (3.0/37.6/39.4)
C/D	30/3 (18.2/1.8)
Tumor size
< 5 cm	119 (72.1)
≥ 5 cm	46 (27.9)
Number of tumors
Single shot	86 (52.1)
Multiple occurrences	79 (47.9)
Lymph node metastasis
Yes	23 (13.9)
No	142 (86.1)
Distant metastasis
Yes	11 (6.7)
No	154 (93.3)
AST
≤ 35 L/I	63 (38.2)
> 35 U/I	102 (61.8)
ALT
≤ 40 I/I	49 (29.7)
> 40 U/L	116 (70.3)
ALP
≤ 135 U/I	127 (77.0)
> 135 L/I	38 (23.0)
GGT
≤ 45 U/I	65 (39.4)
> 45 L/I	100 (60.6)
Cholinesterase
≥ 4300 IL/I	100 (60.6)
< 4300 IL/I	65 (39.4)
TBil
≤ 30 μmol/L	136 (82.4)
> 30 μmol/L	29 (17.6)
Alb
≥ 40 g/L	52 (31.5)
< 40 g/L	113 (68.5)
Hepatic encephalopathy
Yes	7 (4.2)
No	158 (95.8)
Ascites
Yes	38 (23.0)
No	127 (77.0)
Portal vein cancer thrombus
Yes	8 (4.8)
No	157 (95.2)

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyltransferase.